Ocular Gene Therapy
Clinical Trials at the Summit brings together global retina experts
In June, retina experts from around the world will convene in Park City, Utah, to discuss ongoing clinical trials, best trial practices and recent data at Clinical Trials at the Summit.
VIDEO: Gene therapy shows promising disease control for wet AMD in clinical trials
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Carl D. Regillo, MD, discusses promising results for the Ixo-vec gene therapy for neovascular age-related macular degeneration.
VIDEO: Gene therapy-associated uveitis must be mitigated to improve clinical trials
SEATTLE — In this Healio Video Perspective from the Retina World Congress, David Almeida, MD, MBA, PhD, discusses combating gene therapy-associated uveitis.
VIDEO: Gene therapy improves visual acuity in patients with retinitis pigmentosa
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Christine Kay, MD, discusses MCO-010, a gene-agnostic therapy for patients with advanced retinitis pigmentosa.
VIDEO: RGX-314 shows positive results for diabetic retinopathy at 1 year
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilsher Dhoot, MD, shares 1 year results from the phase 2 ALTITUDE trial investigating RGX-314 gene therapy for the treatment of diabetic retinopathy.
ABBV-RGX-314 well tolerated with sustained anti-VEGF protein expression in wet AMD
Subretinal delivery of ABBV-RGX-314 gene therapy demonstrated safety and sustained anti-VEGF protein expression at higher doses in patients with neovascular age-related macular degeneration, according to a study.
Gene therapy improves vision in patients with retinitis pigmentosa in phase 2b trial
MCO-010 demonstrated positive topline results in vision improvement in patients with permanent and severe vision loss from advanced retinitis pigmentosa, according to a press release from Nanoscope Therapeutics.
Lumevoq shows sustained efficacy, safety 4 years after one-time LHON treatment
Lumevoq demonstrated sustained efficacy and a positive safety profile at 4 years after a one-time injection of the gene therapy in patients with Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.
VIDEO: Delivery options for wet AMD gene therapy under investigation
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Lejla Vajzovic, MD, FASRS, discusses developments in gene therapy for wet age-related macular degeneration.
PulseSight Therapeutics launches with focus on non-viral gene therapies
PulseSight Therapeutics, which is developing non-viral gene therapies for retinal diseases, has launched with seed financing from Pureos Bioventures and ND Capital, according to a press release.